Previous 10 | Next 10 |
Revolutionary, micro-invasive, injectable treatment for the full range of glaucoma disease severity iDose TR was designed to usher in a new era of interventional glaucoma by enabling a proactive approach with a safe, effective, and durable therapy for patients in need FDA approval...
2023-12-13 07:22:28 ET Summary The Liberty All-Star Growth Fund focuses on long-term capital growth and has an 8.02% current yield. The fund's share price has declined by 43.23% since June 2021, underperforming the S&P 500 Index. The fund offers exposure to small-cap stock...
2023-12-11 05:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-29 17:24:16 ET Truist has initiated coverage of Glaukos ( NYSE: GKOS ) with a buy rating, citing the company’s glaucoma treatment candidate iDose, which is currently being reviewed by the FDA. The investment firm said it sees Glaukos on the “precipice of a ...
2023-11-08 10:43:10 ET More on Glaukos Glaukos Corporation (GKOS) Q3 2023 Earnings Call Transcript Glaukos: Continued Growth Rates, Regulatory Tailwinds, And Support Sight Sciences slumps amid risk for Medicare coverage for glaucoma procedure Seeking Alpha...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Stifel Healthcare Conference on Tu...
2023-11-01 23:04:08 ET Glaukos Corporation (GKOS) Q3 2023 Earnings Conference Call November 01, 2023 04:30 PM ET Company Participants Chris Lewis - Vice President of Investor Relations & Corporate Affairs Tom Burns - Chairman & Chief Executive Officer Joe...
2023-11-01 16:55:23 ET More on Glaukos Glaukos: Continued Growth Rates, Regulatory Tailwinds, And Support Seeking Alpha’s Quant Rating on Glaukos Historical earnings data for Glaukos Financial information for Glaukos For further details see: ...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2023. Key highlights include:...
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
News, Short Squeeze, Breakout and More Instantly...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 fin...
Shares of Glaukos Corporation (NYSE: GKOS) traded at a new 52-week high today and are currently trading at $120.11. So far today, approximately 152.81k shares have been exchanged, as compared to an average 30-day volume of 541.53k shares. Glaukos Corporation, an ophthalmic medical technology ...
2024-07-01 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...